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ABSTRACT 
 
Antibiotics have been hailed as one of the greatest public health achievements of the 20th 
century, and are a stalwart component of modern medicine. The discovery of penicillin by 
Alexander Fleming in 1929 initiated a period of prolific research and development, in which 
bacterial infections that had previously cut short the lives of scores of infants and adults, were 
halted in their tracks by the power of these new miracle drugs. Antibiotics have been credited 
with saving millions of lives, but the once nearly invincible power of this miracle drug is in 
jeopardy, as a multitude of contributing factors have weakened their efficacy to treat many 
infections. To stem the established and intensifying threat of antibiotic resistance, leadership is 
required from public health entities and the sustained commitment and actions of numerous and 
varied stakeholders. 
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CHAPTER I 
INTRODUCTION 
Background 
 Antibiotics are among the most commonly purchased drugs in the world, and they remain 
the most important tool in the arsenal to controlling many life-threatening bacterial diseases, 
after infection has taken hold (Laxminarayan et al., 2013; United States Department of Health & 
Human Services [U.S. DHHS], 2010). Antibiotics work by instigating bacteria cell damage or 
death, preventing normal cellular functions or reproduction, or disrupting the cell membrane 
(Glover, 2000). Although broad-spectrum antibiotics are effective against a wide array of 
bacterial types and can be used to treat many infections, they may also disturb normal intestinal 
flora, facilitating bacterial overgrowth with emergence of resistant bacteria (Appendix A) 
(Dancer, 2003). Narrow-spectrum antibiotics are used for specifically identified bacteria and are 
therefore less likely to cause a superinfection or drug resistance (SRS Pharmaceuticals 
PVT.LTD, 2014).  
The early use of antibiotics was instrumental in stopping the devastation wreaked by 
meningitis, syphilis, abscesses, and puerperal sepsis, while the use of antibiotics in modern 
medicine is critical in procedures that depend heavily on antibiotics to thwart infections, such as 
heart surgery, joint replacement, dialysis, and organ transplants (Laliberte, 2014; Wright, 2010). 
One study portrayed a dismal future without effective antibiotics, projecting that 30%-40% of 
patients undergoing total hip replacement surgery would develop a post-operative infection, with 
approximately 30% of these patients dying (Laxminarayan et al., 2013).   
Definition and History of Antibiotic Resistance 
While antibiotic use has transformed healthcare, infections from resistant bacteria have 
become commonplace and challenge healthcare providers with dwindling treatment options. 
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Antibiotic resistance (AR) occurs when bacteria evolve in a manner that reduces or eliminates 
the effectiveness of antibiotics to prevent or fight infection (Centers for Disease Control & 
Prevention [CDC], 2013a). Resistance can occur when antibiotics are used inappropriately for 
the wrong illness, or are used erroneously via underuse (Franco, Martinez, Sanchez Rodriguez, 
& Wertheimer, 2009). Antibiotic exposure allows for selective pressure to occur, when surviving 
bacteria with resistant genes continue to multiply, mutating into new, dangerous strains that 
possess a competitive advantage and can share their new genetic information with other bacteria 
(CDC, 2013a; CDC, 2013b). Specifically, treatment of gram-negative bacteria is problematic, 
since the unique nature of their cell wall renders them resistant to several classes of antibiotics 
and increasingly difficult to defeat (U.S. DHHS, 2012). Furthermore, multidrug-resistant 
organisms (MDROs), that are resistant to one or more classes of antibiotics, require the use of 
second or third choice drugs that have less desirable side effects or attributes. AR has now 
extended beyond the confines of the healthcare environment and has exhibited an alarming 
increase in the community setting where skin infections and sexually transmitted disease are 
becoming more difficult to treat successfully (McCoy, Toussaint, & Gallagher, 2011).  
Recent, heightened efforts by public health officials have attempted to elevate awareness 
and action regarding this threat, yet for nearly 20 years, concern for this burgeoning crisis has 
often fallen on deaf ears. In a 1945 interview with The New York Times, Alexander Fleming 
warned that overreliance on antibiotics could lead to the widespread emergence of resistant 
bacteria and his prediction rang true (Rosenblatt-Farrell, 2009). The 1940s saw the discovery of 
AR in a β-lactamase-producing strain of S. aureus, but the arrival of methicillin in 1959 allowed 
providers to treat strains that had developed resistance to penicillin (Franco et al., 2009; Walsh & 
Fischbach, 2009). Vancomycin  was approved by the U.S. Food & Drug Administration (U.S. 
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FDA) in 1958 and became the drug of choice for treating methicillin-resistant S. aureus 
(MRSA), as the strain became widespread in healthcare facilities and the community setting 
(Walsh & Fischbach, 2009). In 2002, the inevitable occurred as strains of Vancomycin-resistant 
S. aureus (VRSA) began appearing in hospitals, forcing a renewed warning that the Golden Age 
of antibiotics had come to an end (Walsh & Fischbach, 2009). The incidence of these and other 
antibiotic resistant organisms have reached unmatched levels, impacting patient treatment and 
outcomes in all specialties and arenas (Strausbaugh, Siegel, & Weinstein, 2006).  
AR is an urgent and escalating crisis, complicated by the actions of healthcare, the 
pharmaceutical industry, agriculture, and the community (Lancet Infectious Diseases, 2013). 
Although AR cannot be prevented, its development and spread can be mitigated through 
concerted commitment and action and judicious use, to ensure the ability to control disease is not 
extinguished (Wright, 2010). In December 2013, the CDC once again sounded the alarm and 
declared AR a 2014 health challenge, stating, “We are approaching a cliff. If we don’t take steps 
to slow or stop drug resistance, we will fall back to a time when simple infections killed people” 
(CDC, 2014h, p. 1).  
Prevalence in the United States 
 Studies have found that antibiotic use rates differ among countries, and those with the 
highest rates of per capita antibiotic consumption are subject to the highest rates of drug 
resistance (Bisht, Katiyar, Singh, & Mittal, 2009). Estimates based on conservative assumptions 
by the CDC allege that every year in the U.S., more than two million people become ill with 
antibiotic resistant infections and at least 23,000 of these individuals die (CDC, 2013b). Those 
who become infected with antibiotic resistant organisms are often subject to deadly or life-
altering consequences due to protracted illnesses, extended hospital stays, and the need for 
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treatment with more toxic or less effective drugs. Annually, AR in the U.S. costs $20 billion in 
surplus healthcare costs, $35 million in other societal costs, and results in more than 8 million 
extra days that people are hospitalized (National Institute of Allergy & Infectious Diseases 
[NIAID], 2014). Multiple studies have found an association between AR and poor outcomes 
with patients with resistant infections facing a 1.3 to 2 times increase in morbidity and mortality, 
when compared with patients being treated for susceptible bacterial infections (Franco et al., 
2009). Antibacterial resistance has surfaced in nearly every nosocomial pathogen, with the most 
commonly arising bacterial healthcare-associated infections (HAIs) occurring in the U.S. caused 
by coagulase-negative Staphylococci, S. aureus,  Enterococcus, and Gram-negative bacteria such 
as Escheria coli, Pseudomonas, Klebsiella, Acinetobacter, and Enterobacter species (National 
Institutes of Health [NIH], 2010). Over 70% of HAIs are caused by strains resistant to at least 
one treatment drug of choice, placing highly susceptible immunocompromised and critically ill 
patients in acute jeopardy (NIH, 2010). 
Types of Resistant Organisms 
 In 2013, the CDC released a report prioritizing resistant bacteria into one of three 
categories, urgent, serious, and concerning based on their assessment on domestic impact (CDC, 
2013b). Assessment factors included clinical impact, economic impact, incidence, 10-year 
projection of incidence, transmissibility, availability of effective antibiotics, and barriers to 
prevention (CDC, 2013b).  
 Urgent Level Threats 
Urgent level threats are high-consequence antibiotic resistant threats because they pose 
significant risks identified across several criteria. Although these threats currently lack 
widespread reach, they have the potential to become pervasive and require urgent public health 
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attention to identify infections and to limit transmission (CDC, 2013b). Urgent level threats 
include Carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria 
gonorrhoeae (Appendix B). CRE are rapidly spreading through healthcare facilities across the 
country and have become resistant to nearly all the antibiotics in use today (CDC, 2013b). 
Carbapenems are broad-spectrum antibiotics considered to be the last resort drug for treatment of 
serious gram-negative infections, and once bacteria develop resistance to carbapenems, they 
often become resistant to all β-lactams (CDC, 2013b). Nearly 50% of patients who acquire CRE 
infections will die, resulting in over 600 annual deaths (CDC, 2013b). Gonorrhea, which causes 
severe reproductive complications, is the second most commonly reported infectious disease in 
the U.S., and drug-resistant Neisseria gonorrhoeae is present in 30% of all cases (CDC, 2013b; 
NIAID, 2012). Cephalosporins are part of the first-line treatment, but if cephalosporin-resistant 
N. gonorrhoeae becomes widespread, the result could be an additional 75,000 cases of pelvic 
inflammatory disease, 15,000 cases of epididymitis, and 222 cases of HIV over 10 years, with 
additional direct medical costs of $235 million (CDC, 2013b).  
Serious Level Threats 
Serious level threats are substantial antibiotic resistant threats owing to low or decreasing 
incidence in the U.S. or reasonable availability of effective antibiotics. However, these threats 
will worsen and become urgent unless public health surveillance and prevention activities are 
sustained (CDC, 2013b). The CDC identifies 11 resistant bacteria as a serious threat (Appendix 
B). Multi-drug resistant Acinetobacter is a gram-negative bacterium responsible for pneumonia 
or bloodstream infections among critically ill patients and it has also complicated treatment of 
wound infections in U.S. military personnel (NIAID, 2012). Approximately 63% of 12,000 
Acinetobacter HAIs are multi-drug resistant, resulting in 500 deaths (CDC, 2013b). 
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Campylobacter is spread through contaminated food, or resistant strains can develop due to 
antibiotic use in food animals, which can then spread to humans (CDC, 2013b). Campylobacter 
is resistant to ciprofloxacin in almost 25% of tested cases and is resistant to azithromycin almost 
2% of the time (CDC 2013b). Resistance has nearly doubled from 1997 (13%) to 2011 (25%) 
(CDC, 2013b). Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) contain 
an enzyme that permits them to gain resistance to a wide variety of penicillins and strong 
cephalosporins (CDC, 2013b). Enterobacteriaceae are responsible for $40,000 in surplus hospital 
expenses per case, and patients with resultant bloodstream infections are 57% more likely to die 
than individuals with a bloodstream infection caused by a non ESBL-producing strain (CDC, 
2013b). Enterococci are the fifth most common reason for HAIs and produce a variety of 
illnesses, including infections of the bloodstream, surgical sites, and urinary tract (CDC, 2013b; 
Solomon & Oliver, 2014). Vancomycin-resistant enterococcus (VRE) strains leave providers 
with minimal or no treatment options. While the overall incidence of invasive MRSA is waning 
and there are multiple effective antibiotics available, the number of invasive MRSA infections is 
among the highest of all antibiotic resistant threats at over 80,000 cases annually, and the 
proportion of community-associated infections is on the rise (CDC, 2013b; Solomon & Oliver, 
2014). MRSA has the potential to be upgraded to urgent threat status if infection rates increase or 
strains become more resistant (CDC, 2013b). Streptococcus pneumoniae is the chief cause of 
bacterial meningitis and pneumonia in the U.S., and in 30% of severe S. pneumoniae cases, the 
bacteria are fully resistant to one or more front-line antibiotics (CDC, 2013b). S. Pneumoniae 
resistant infections account for more than 1.2 million illnesses and 7000 deaths annually, and the 
associated healthcare costs approach $96 million (CDC, 2013b). In the U.S., Mycobacterium 
tuberculosis is generally treatable with first-line tuberculosis (TB) drugs (CDC, 2013b). Drug-
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resistant TB and Extensively Drug-Resistant TB (XDR TB) are complex infections to treat, 
necessitating lengthy treatments and more costly drugs, with direct costs averaging $134,000 per 
drug-resistant TB patient and $430,000 per XDR TB patient, as compared to $17,000 per drug 
susceptible TB case (Marks et al., 2014). In the U.S., most cases of drug-resistant TB occur in 
individuals who were born outside of the country (CDC, 2013b). The complete list of serious 
threat level antibiotic resistant organisms can be found on Appendix B. 
Concerning Threats 
Although the CDC has identified 13 drug-resistant bacteria as the most dangerous threats 
in the U.S., other bacteria remain dynamic and resilient, which poses as a looming threat. The 
CDC has designated three antibiotic resistant organisms, Vancomycin-resistant Staphylococcus 
aureus (VRSA), Erythromycin-resistant Streptococcus Group A, and Clindamycin-resistant 
Streptococcus Group B, as hazard level concerning (CDC, 2013b) (Appendix B). While these 
organisms either have a low threat of AR and/or are still susceptible to a variety of therapeutic 
choices, they are capable of producing severe morbidity or death and necessitate ongoing 
surveillance, to quickly address an outbreak or escalation in incidence (CDC, 2013b).  
As of May 2014, there have been only 13 confirmed cases of VRSA in the U.S. and no 
deaths (CDC, 2014b). While incidence is rare, Vancomycin-resistant strains of are growing 
concern, since Vancomycin is often considered the drug of last resort and many VRSA strains 
are also resistant to methicillin and other classes of antibiotics (CDC, 2013b). Several 
circumstances seem to predispose patients to VRSA infections, including previous history of 
infections or colonization with MRSA or enterococcus, underlying chronic conditions or disease 
(skin ulcers, diabetes), and past treatment with Vancomycin. These factors underlie the 
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importance of sound infection prevention practices and prudent prescribing habits, to keep this 
threat at bay (CDC, 2013b).  
Group A Streptococcus (GAS) is responsible for strep throat, streptococcal toxic shock 
syndrome, necrotizing fasciitis, scarlet fever, and rheumatic fever, and can lead to invasive 
disease placing infected children, the elderly, those residing in group living facilities, and 
individuals with chronic conditions, at increased risk for detrimental outcomes (CDC, 2013b). 
Invasive erythromycin-resistant GAS causes 1,300 illnesses and 160 deaths in the U.S. annually 
(CDC, 2013b).  
Group B Streptococcus (GBS) can cause a variety of illnesses across the lifespan, from 
life-threatening meningitis and pneumonia in newborns, to sepsis and bone and joint infections in 
adults (CDC, 2013b). In 2011, 28% of GBS samples exhibited resistance to clindamycin, and 
clindamycin-resistance has progressively risen since 2000 (CDC, 2013b). Increased incidence of 
GBS resistance to second-line antibiotics, such as clindamycin and erythromycin will further 
hamper provider efforts to effectively treat patients with GBS who are allergic to penicillin 
(CDC, 2013b).  
Purpose of Paper 
AR is a pressing, widespread threat to the health and welfare of all Americans. The 
purpose of this paper is to identify the numerous multifaceted factors that contribute to the 
surging prevalence of AR, explore existing gaps that are impeding endeavors to tackle this 
danger, and examine present strategies and future requisites to assuaging AR. While the U.S. is 
facing a multitude of competing public health events such as chronic disease that receive more 
recognition, it is critical to raise cognizance about the gravity of healthcare without an effective 
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arsenal of antibiotics, in order to generate unremitted action from the public and a diverse array 
of stakeholders, and turn the tide on this accelerating threat. 
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CHAPTER II 
CONTRIBUTING FACTORS 
 
 The threat of AR cannot be attributed to a single influence, but is magnified by a 
combination of factors and influences from both within and outside of the healthcare 
environment. Mitigation of these factors requires both elucidation and cognizance of their unique 
effects and impacts on AR, to delineate and develop future solutions. 
Factors 
Overprescribing 
 The key driver behind AR is the sheer quantity of antibiotic consumption, and both the 
inappropriate use of antibiotics and the overprescribing of broad-spectrum antibiotics contribute 
to the threat. These poor treatment decisions occur in healthcare facilities and in the community. 
One study in 2006 found that 80% of the over 132 million outpatient antibiotic prescriptions 
were written by primary care and emergency department providers, not infectious disease 
specialists (Roberts et al., 2009). When antibiotics are taken unnecessarily, there is no 
therapeutic benefit to the recipient, but great potential for harm for the individual and community 
at large (Fridkin et al., 2014). While research has shown the percentage of time antibiotics were 
prescribed for adult, acute respiratory tract illness visits has fallen from near 60% to 49% in the 
past 20 years, in a majority of those cases unwarranted and ineffective broad-spectrum 
antibiotics were ordered (CDC, 2011; Laliberte, 2014). Treatment indication, choice of drug, or 
duration of therapy can be incorrect in up to 50% of the cases in which antibiotics are prescribed 
(CDC, 2013b). For hospitalized adult patients outside of critical care units, up to 30% of 
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prescribed antibiotics are unneeded, underscoring an opportunity for reducing incorrect 
prescribing by providers (CDC, 2013b).  
The statistics regarding treatment of pediatric illnesses and antibiotic use also justify 
continued scrutiny and modification. While evidence supports that overall utilization of 
antibiotics in pediatric populations has declined over the past twenty years, mainly due to 
changes in practice guidelines for treatment of otitis media, the decline appears to have plateaued 
and parental pressure remains a significant factor in provider’s choice for treatment (Greene et 
al., 2012). Providers may feel that they are between a rock and a hard place, as they struggle 
between their obligation to treat each patient as effectively as possible, which may be with the 
latest broad-spectrum antibiotic for which resistance is less common, with their responsibility to 
abate the escalating threat of AR for the greater good (Roberts et al., 2009). One survey found 
that 95% of clinicians prescribe antibiotics even if they are not absolutely certain they are 
appropriate, due to delays in diagnostic lab results or patient pressure, and 10% of clinicians 
believe that the antibiotic will not result in any harm if the antibiotic is unnecessary (Lowes, 
2014). Several studies examining influences on prescribing habits have found that decisions on 
when to prescribe antibiotics can be guided by where clinicians received their training, the 
number of years they have practiced, and their type of practice (public versus private) (Franco et 
al., 2009). Another study that examined prescribing etiquette found existence of a shared tenet of 
noninterference in the practice of fellow providers, preventing physicians from questioning or 
intervening in the antibiotic prescribing behavior of their associates (Charani et al., 2013). While 
overprescribing is just one component of the resistance challenge, improved provider and patient 
education on proper need and usage of antibiotic therapy, and increased access to rapid 
diagnostic testing, may be beneficial components of future strategies. 
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Use in Agriculture 
 The traditional use of antibiotics in agriculture has also been implicated in contributing to 
the mounting level of resistance. Antibiotic resistant infections due to food-borne organisms are 
responsible for 430,000 illnesses in the U.S. annually (CDC, 2014a). In 2011, 29.9 million 
pounds of antibiotics were sold in the U.S. for use in meat and poultry production, compared to 
7.7 million pounds of antibiotics that were sold to treat human illness (Pew Charitable Trusts, 
n.d.). Years of lax regulation and unsupervised use of antibiotics by the agriculture industry has 
contributed to the emergence of antibiotic resistant bacteria. Resistant bacteria thrive in animal 
carriers, and the bacteria is then transmitted to humans through the food supply via improperly 
handled or undercooked meat where the bacteria spread, continue to thrive, and produce adverse 
health outcomes in humans (CDC, 2013b). Resistant bacteria can also be propagated when 
fertilizer or water containing animal feces tainted with drug-resistant bacteria is applied on food 
crops, and the contaminated produce is consumed by humans (CDC, 2013b). Approximately 
75% of the antibiotics used in animals have human counterparts, and therefore resistance to 
antibiotics used in poultry and livestock could translate into resistance to a human drug (DeWaal 
& Grooters, 2013; U.S. FDA, 2013a). For years, antibiotics have been utilized by farmers in 
animal feed to prevent infection among animals living in overcrowded, unsanitary living 
conditions, to control disease in a group of animals when some animals exhibit signs of illness, 
and to facilitate growth in healthy animals so they can be sold earlier for profits and supply 
cheap meat to consumers (Laliberte, 2014; U.S. FDA, 2013a). There is also significant 
variability in the use of antibiotics for therapeutic or prophylactic use. For example, one analysis 
found that 16% of all lactating dairy cows in the U.S. were given antibiotics for treatment of 
mastitis, but nearly all cows were given prophylactic doses of penicillins, cephalosporins, or 
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other β-lactam drugs, to prevent future mastitis (Landers, Cohen, Wittum, & Larsen, 2012). 
While large-scale confined animal feeding operations (CAFOs) permit operators to reduce costs 
for labor, feed, and housing, these conditions make animals more susceptible to disease (DeWaal 
& Grooters, 2013). Robust circumstantial support suggests that resistance genes circulate among 
people, animals, and the environment, though the exact route of spread can be more difficult to 
pinpoint (Laxminarayan et al., 2013). The ability of MRSA to spread from animals to humans 
via direct contact is well known, and food-borne transmission of non-typhoid salmonella and 
campylobacter, including resistant strains, has also been reported (Laxminarayan et al., 2013). 
Data collected by the National Antimicrobial Resistance Monitoring System (NARMS) in 2011 
found that more than 27% of all chicken isolates exhibited resistance to five or more classes of 
antibiotics, and researchers discovered 10 different serotypes with resistance to six or more 
classes of antibiotics in ground turkey samples (Bottemiller, 2013). Following the 1940’s 
discovery of the growth-promoting properties of sub therapeutic antibiotic doses, which aided in 
reducing illness and allowing animals to put on weight, the addition of antibiotics to animal feed 
and water quickly became a routine part of animal husbandry in the U.S. (Laliberte, 2014; Lewis, 
2013). Between 2001 and 2010, the U.S. FDA performed a safety review of 30 penicillin and 
tetracycline antibiotic feed additives currently approved for non-therapeutic use in poultry and 
livestock, and determined that 18 of the 30 additives were likely to pose a high risk of exposing 
humans to antibiotic resistant bacteria via the food supply, and that at least 26 of the additives 
failed to meet the safety standards set by the U.S. FDA in 1973 (Cordova & Kar, 2014). As of 
January 2014, at least nine of these antibiotic additives were still being marketed for growth 
promotion or prevention of disease (Cordova & Kar, 2014). While the controversy over the use 
in antibiotics in animals and its impact on human health has been ongoing for over 50 years, 
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renewed focus on this relationship is fueled by the mounting threat of AR, prompting increased 
oversight by government agencies and demand for producer accountability (Laxminarayan et al., 
2013).  
Antibacterial Products 
 The use of antibacterial agents, such as hand sanitizers, hand wipes, or antibacterial 
soaps, have been found to be useful and appropriate in hospitals and nursing homes, but the risks 
versus benefits of consumers using antibacterial soaps and body washes in the public setting is 
receiving increased inspection (U.S. FDA, 2013b). 
Antibacterial soap products contain the chemical triclosan, which may contribute to 
bacterial resistance to antibiotics when they are used regularly and over an extended period of 
time (U.S. FDA, 2013b). Triclosan is an agent effective against Gram-negative and Gram-
positive bacteria and it has been incorporated into numerous household products for the last 30 
years (CDC, 2013d; Cullinan, Bird, Heng, West, & Seymour, 2014). There is a lack of research 
and evidence as to whether or not antibacterial soaps are more effective than diligent hand 
washing with soap and water. When product laboratories evaluate the effectiveness of 
antibacterial products, it does not include testing to determine the effectiveness of the product on 
infection rates (U.S. FDA, 2013b). Triclosan can be absorbed orally or through the skin, and a 
study by the CDC found that triclosan was present in the urine of 75% of those tested (CDC, 
2013d; Landau & Young, 2014). Because the evidence linking triclosan to AR and adverse 
health outcomes is scarce and mixed, where some studies are inconclusive in proving the 
development of resistance to antibiotics due to protracted exposure to triclosan and other in vitro 
studies have verified this link, the potential of a public health risk cannot be ruled out at this time 
(CDC, 2013a; Saleh, Haddadin, Bailllie, & Collier, 2011). An additional concern by some health 
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experts is the belief that the increased use of antibacterial products by the public may foster a 
false sense of security and cause individuals to become lax in basic, proven hygiene habits for 
preventing disease transmission (Alliance for the Prudent Use of Antibiotics, n.d.).  
Lack of Public Knowledge 
 While consumers have positive attitudes about antibiotics, they may lack knowledge 
about how these drugs work and for which diseases they are effective, spurring a lackadaisical 
perception about their essential role in saving lives, as the days of when people routinely died 
from a cut or childbirth fever have long been forgotten. When examining the demand side of 
antibiotic use, it appears that overuse or irrational use of antibiotics has become a social norm, 
and their power has been taken for granted (Laxminarayan et al., 2013). Patient demand for 
antibiotics is driven by numerous factors including patient characteristics, such as age, gender, 
income, ethnicity, level of education, personal hygiene, illness, social and family environments, 
and community resources (Franco et al., 2009). Many providers believe that when a patient seeks 
treatment for illness, the patient does not expect to leave the office empty-handed; it is implicit 
that the patient desires antibiotics (Stokowski, 2014). A clash may exist between patient 
satisfaction and the practice of judicious antibiotic prescribing, as patients may equate 
satisfaction with receiving an antibiotic and may threaten providers with poor satisfaction 
ratings, or accusations of providing inadequate care based on race or insurance status if the 
patient doesn’t receive what they desire (Stokwski, 2014).  
Several studies have found that awareness about AR is deficient in some of the more 
educated segments of the U.S. population. A study among elderly residents in England found 
that 26% of respondents believed that antibiotics would cure a cold, and 50% expected to receive 
a prescription for antibiotics if they visited the provider with cold symptoms (Mahmood, Naqvi, 
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& Grewal, n.d.). Research has shown that providers are more likely to succumb to demands for 
antibiotics for elderly and pediatric patients (CDC, 2011; Mahmood et al., n.d.). Physicians 
prescribed antibiotics 62% of the time for their pediatric patients, if they believed the parents 
expected them (CDC, 2011). Studies specifically examining public knowledge and 
understanding about resistant bacteria, such as MRSA, imply that the public does not usually 
perceive a relationship between “superbugs” and antibiotic use (Norris et al., 2013). Many 
patients attribute the cause of and responsibility for AR to external factors, as opposed to their 
personal beliefs and actions, and therefore believe the solutions for AR are beyond their control 
(Brooks, Shaw, Sharp, & Hay, 2008). These findings may present an opportunity for public 
health stakeholders to modify or develop educational campaigns, and to increase public 
awareness and understanding about the severity of AR and the need for timely action. 
Lack of Knowledge Among Healthcare Workers 
 Research from healthcare facilities shows that antibiotic prescribing habits are influenced 
by attitudes, social norms, and beliefs, but when facilities address the issue of overprescribing, 
they often focus only on the role of the physician, negating the complex social network of nurses, 
pharmacists, and other healthcare workers doctors interact with, who may also influence 
prescribing behavior (Charani et al., 2013). In the healthcare realm, the cultural hierarchy may 
inhibit nurses and pharmacists from challenging the decision-making of doctors in regards to 
antibiotic treatment (Charani et al., 2013). However, studies have also shown that healthcare 
workers may lack solid knowledge about the serious threat of AR, how it is promoted, and what 
their role is in modulating the problem. Since healthcare workers are often the culprits in the 
transmission of MRSA and other HAIs in hospitals and long-term care facilities (LTCFs), 
understanding their perception and beliefs about the dangers of AR is also a key component in 
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developing prevention and control strategies (Wolf, Lewis, Cochran, & Richards, 2008). One 
survey of nurses and nursing assistants in a LTCF found they perceived MRSA and AR to be a 
greater problem on the national level than at their facility, which correlates with findings in other 
settings and among other healthcare workers (Wolf et al., 2008). Alzoubi et al. (2009) conducted 
a study to discern awareness of AR among physicians, pharmacists, and nurses and found 
significant differences about knowledge of commonly encountered resistant strains, the factors 
promoting resistance, and the strategies necessary to halt the threat. Several studies have also 
queried students in medicine, nursing, and healthcare to determine their knowledge of infection 
control and management of antibiotic resistant bacteria and found that many students were 
lacking a solid knowledge base, and curriculums were deficient in critical content (Jennings-
Sanders & Jury, 2010). Examination of healthcare workers’ perceptions and continuous medical 
education programs may present an opportunity to empower staff and garner buy-in, to solidify 
their role in being patient advocates and educators concerning AR. 
Dearth of New Antibiotics  
 Because AR can only be slowed, not ended, due to the natural process of bacterial 
evolution, new antibiotics must be developed for medicine to have viable options for treating 
infections (CDC, 2013b). Yet the number of new antibiotics developed and approved for use has 
substantially dwindled over the past thirty years, even as AR has accelerated (CDC, 2013b). 
During the golden age of antibiotic discovery between 1929 and the 1970s, more than 20 new 
classes of antibiotics were approved and marketed, yet since then, only two new classes of 
antibiotics have achieved the same fate (Laxminarayan et al., 2013). Some researchers suggest 
that to return to a more secure and effective arsenal of treatment options, the world will need to 
develop and net approval for nearly 20 new classes of antibiotics within the next 20 years 
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(Laxminarayan et al., 2013). In the 1980’s a feeling of complacency prevailed throughout the 
drug companies as they believed that bacterial infections were under control, and they directed 
their resources to new, pressing areas of concern (Lewis, 1995). This erroneous line of thinking 
coupled with the prolific overuse of antibiotics contributed to the perilous state today. The fragile 
antibiotic pipeline is in jeopardy of drying up as numerous pharmaceutical companies have 
terminated their research and development (R&D) programs for antibiotics due to an array of 
factors. Each new, approved antibiotic can cost between $800 million to $1.7 billion to develop, 
but yields meager dividends when compared to the latest and greatest drug to treat insomnia or 
hypertension (World Health Organization [WHO], 2011).  
The regulatory environment is another impediment for antibiotic development as the U.S. 
FDA requires three phases of clinical trials to test the efficacy and safety of new drugs, and the 
third phase requires testing on large numbers of people, which is an arduous task, since a 
relatively few number of people contract these infections and are eligible to participate in clinical 
trials (Pew Charitable Trusts, 2014c; Schwartz, 2013). Historically, only one out of five drugs 
that make it to the first stage of human trials will be granted approval by the U.S. FDA (Pew 
Charitable Trusts, 2014c). As of June 2014, there were 43 new antibiotics in development, with 
seven drugs in phase 3, which has a historical approval rate of 60% (Pew Charitable Trusts, 
2014c). It is more profitable for pharmaceutical companies to invest their resources into drugs 
for chronic diseases, medications that individuals must take for many years, as opposed to 
antibiotics, which cure disease and are taken for a comparatively shorter length of time (Wright, 
2010). Others have hypothesized that antibiotics developed over 50 years ago from natural 
products or their derivatives isolated from soil bacteria were the “low-hanging fruit,” and that 
drug companies will need to formulate strategies for developing novel antibiotics (Franco et al., 
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2009; Wright, 2010). It is more challenging to discover new drugs to treat Gram-negative 
because their double cell wall makes it more difficult for antibiotics to penetrate and ultimately 
kill the bacteria (Schwartz, 2013). While ideas for antibiotic discovery can be generated by small 
companies and scientists in academia, the costly and protracted research and design process 
greatly hampers progress. The average cost of a phase 3 clinical trial is approximately $70 
million, essentially mandating the financial backing and participation of major pharmaceutical 
companies (Laxminarayan et al., 2013).  
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CHAPTER III 
GAPS IN COMBATTING ANTIBIOTIC RESISTANCE 
 
Stakeholder Perception and Pushback  
While the adage “perception is reality” may have first been used in the context of politics, 
it also appears to place a pivotal role in the overuse of antibiotics. When queried about the issue 
of widespread antibiotic prescribing, healthcare providers often voice that they believe the 
patient is driving the national obsession with the wonder drug. Though surveys show some 
physicians often feel patients persistently hound them for unwarranted antibiotics, it seems fair to 
question whether or not provider perceptions of patient expectations and desires correlates with 
what the patient actually wants (Stokowski, 2014). Are providers more apt to prescribe 
antibiotics if they believe that patients are seeking them? Providers may also perceive that 
educating patients on the perils of overuse during a sick visit is a fruitless task in a country where 
the prevailing culture is to pop pills recklessly to avoid the inconvenience of a mild illness 
(Stokowski, 2014). This behavior is concerning, since only about 50% of patients claim that their 
doctors discussed the risks versus benefits of antibiotic use with them, yet an association has 
been detected between a patient’s lack of participation in a physician visit and the patient’s lack 
of comprehension about their medications (Franco et al., 2009; Lowes, 2014).  
Beliefs about the role, risks, and benefits of antibiotics in food animals have led to 
opposition from many stakeholders in the agriculture industry who have used drugs for many 
years to protect their livelihood. The old days of farming were dominated by the mantra, “if 
some is good, more is better,” as large doses of antibiotics were used to prevent and control 
diseases in the entire herd, rather than on an individual basis, with minimal supervision from 
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veterinarians (Lewis, 2013). While many influential players in the agriculture industry support 
ongoing collaborative efforts between the industry and health agencies to curb the spread of AR 
in humans, others claim the numbers quoted by the U.S. FDA are inflated and give an unfair 
picture of the volume and classes of antibiotics used in husbandry, many of which are not used 
for human treatment (Hall, 2013). Per the U.S. Farmers & Ranchers Alliance (n.d.), about 1/3 of 
the antibiotics consumed by food animals are ionophores, which are not utilized to treat humans, 
producing minimal impact on public health if resistance develops. They also assert that in 
countries where the complete elimination of antibiotics to mass prevent or control disease in 
farm animals has occurred, it has led to an increased need for treatment with newer, stronger 
antibiotics that are similar to those used in human medicine (U.S. Farmers & Ranchers Alliance, 
n.d.). Critics of increased antibiotic oversight also raise concerns that stoppage of sub therapeutic 
dosing will result in producers having to feed their livestock and poultry more grain to get them 
up to market weight, which will lead to a costly increase in meat prices and consumer rejection 
(Dillon, 2010). The viewpoints maintained by industry producers may challenge the new AR 
guidelines for livestock and poultry released by the U.S. FDA in late 2013, in their efforts to 
implement multisectoral solutions. 
Finally, antibiotics are uniquely distinguished from other drugs in that the effects of their 
use extend beyond the individual patient (Laxminarayan et al., 2013). The singular choice of a 
provider to succumb to patient pressure and prescribe an unnecessary antibiotic, or the actions of 
a consumer to doctor shop until they get the antibiotic they desire may be fueled by a belief in 
short-term benefits, but this practice not only subjects the individual to personal risk, but can also 
jeopardize future treatment options for the larger community as a whole. Who should decide 
what and how regulations and programs are developed and enforced, to ensure the country will 
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be able to effectively treat infections in the future? Should there be equal accountability among 
providers, patients, and industry stakeholders regarding antibiotic distribution? Some ethicists 
have proposed that access to antibiotics creates a collective action issue, because the more they 
are used, the more selective pressure is placed on bacteria to evolve and share genetic 
information, which promotes AR in the greater environment (Anomaly, 2013). The burden of 
oversight must be championed and weighed carefully by public health stewards, since individual 
rights and regulations must be balanced, or people may ignore the risks they levy on others, due 
to lack of awareness, or indifference (Anomaly, 2013). 
Issues with Identification, Transparency, and Regulation 
One barrier frequently cited by providers in their uncertainty in making treatment 
decisions regarding infections is the scarcity of rapid diagnostic testing, which may promote 
irrational use of antibiotics. Culture-based assays are the gold standard for organism 
identification and susceptibility testing, but pathogen identification and susceptibility results 
require a minimum of 24 hours and 48 hours respectively (Laxminarayan et al., 2013). This lag 
time between when a patient presents to the clinician and a definitive organism identification can 
force providers to make a judgment call about antibiotic treatment, knowing that timely, 
effective treatment decreases the risk of morbidity and mortality in severe infections 
(Laxminarayan et al., 2013). With a lack of accurate, cost-effective rapid test results to pinpoint 
an illness as bacterial or viral in origin, providers may fear missing the subtle signs of a serious 
illness and adopt a better safe than sorry attitude, leading to overprescribing (Stokowski, 2014).  
Another barrier is the inconsistent regulation and selective, haphazard reporting of HAIs 
around the country. HAIs are common, costly, and often preventable, and most deaths related to 
AR occur in hospitals and nursing homes (CDC, 2013b). In healthcare settings, the spread of 
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resistant bacteria can be rapid, with severe consequences for compromised patients, and over 
70% of the bacteria that cause infections acquired in acute care facilities are resistant to at least 
one commonly used drug (Kisuule, Wright, Barreto, & Zenilman, 2008; Laxminarayan et al., 
2013). Furthermore, after patients who fought HAIs are discharged from the hospital, healthcare 
workers and patient visitors can become carriers, enabling the dissemination of resistant bacteria 
within the community (Franco et al., 2009). While all 50 states now have HAI surveillance and 
prevention programs, not all states have laws requiring data submission and or public reporting 
(Reagan, n.d.). A 2012 report found that only 21 states had legislation that required monitoring 
and reporting of surgical site infections, one type of HAI, and only eight of those states publicly 
reported the data on just ten types of procedures (CDC, 2014c; Koleva, 2012). Thirty-one states 
now mandate the release of hospital infection information (Anders, 2014). Full public disclosure 
of HAIs has been shown to have a substantial bearing on improving healthcare quality, since 
patients may be empowered and better informed to compel hospitals to reassess their practices 
and improve quality (Koleva, 2012). While HAIs can be caused by a variety of factors, greater 
public transparency about their occurrence and the role that improper use of antibiotics can play 
in propagating drug resistant organisms, may increase awareness among stakeholders and 
cultivate change.  
In 2006, the European Union banned the use of growth promoting antibiotics in food-
producing animals, due to the potential threat to human health, but the U.S. has been slow to 
implement comparable measures (McElroy, 2010). In 2012, the U.S. FDA published a guidance 
document for the agriculture and livestock industries, in an endeavor to allay the risk of AR to 
public health (U.S. FDA, 2013a). The guidelines concentrated on two central standards “1) 
limiting medically important antimicrobial drugs to uses in food-producing animals that are 
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considered necessary for assuring animal health; and 2) limiting such drugs to uses in food-
producing animals that include veterinary oversight or consultation” (U.S. FDA, 2013a, p. 1). 
Industry watchdogs claimed these guidelines were largely disregarded by producers (Pierson & 
Abbott, 2013). In December 2013, the U.S. FDA released updated voluntary direction to phase 
out the use of antibiotics as a growth enhancer over the next three years, and they have also 
asked pharmaceutical and global health companies to revise labels of antibiotics important in 
treatment of human infections and remove any references to use in animal production (Pierson & 
Abbott, 2013). Pharmaceutical companies had three months to notify the U.S. FDA of their 
intent to comply and will now have three years to conform to standards, or the U.S. FDA can 
take action against them (U.S. FDA, 2014). The U.S. FDA believes that a voluntary, 
collaborative approach is the quickest way to implement change, since regulatory action would 
entail the agency evaluating each drug. This would likely cause substantial disruption to the 
agriculture and animal health industries and would necessitate significant allocation of agency 
resources for methodical monitoring (U.S. FDA, 2014). These new guidelines have also been 
criticized by advocates for food safety and public health for being weak, difficult to enforce, and 
lacking metrics for success (National Sustainable Agriculture Coalition, 2013; Pierson & Abbott, 
2013).  
 The CDC has implemented several systems in healthcare facilities and in the community 
setting to track AR in all bacteria and antibiotic usage (CDC, 2013b). The National Healthcare 
Safety Network (NHSN) is utilized by healthcare facilities for reporting data. The National 
Antimicrobial Resistance Monitoring System (NARMS) is a collaboration among the CDC, U.S. 
FDA, U.S. Department of Agriculture (U.S. DA), and state and local health agencies to track AR 
among Salmonella, Campylobacter, and other bacteria regularly spread via food (CDC, 2013b). 
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Tracking infection and resistance in the community occurs through the Active Bacterial Core 
surveillance (ABCs), the Gonococcal Isolate Surveillance Project (GISP), the National 
Tuberculosis Surveillance System (NTSS), and the Healthcare-Associated Infections-
Community Interface (HAIC) (CDC, 2013b). However, to overcome inconsistent surveillance 
and data collection around the nation and ensure regular tracking of resistant bacteria, funding 
must be sustained even as numerous public health issues compete for scarce resources. The 2015 
President’s Budget requests $30 million annual funding for the CDC’s Antibiotic Resistance 
Initiative to achieve measurable results among four actions, including the detection and tracking 
patterns of AR (CDC, 2014c). While the U.S. has systems in place to assess the prevalence of 
AR, many countries around the world lack the infrastructure and resources to conduct adequate 
surveillance and reporting. This is a concern since diseases know no boundaries, and worldwide 
ease of travel enables disease threats to be only a car ride or plane trip away. 
Prevalence and Challenges in Vulnerable Populations  
 The intensifying shortfall of effective antibiotic treatments makes it challenging to treat 
infectious diseases in members of vulnerable populations, whose medical care may be 
complicated by additional health, social, and environmental determinants. As more Americans 
are living longer with complex chronic diseases, many find themselves living in long-term care 
facilities where close quarters, frequent social interaction, and low immunizations make the 
environment a hot zone for the rapid spread of antibiotic resistant organisms (Chilton, 2004). A 
significant proportion of antibiotic use in nursing homes is unwarranted, as many decisions to 
initiate antibiotics are made over the phone and without the benefit of a physical assessment by 
the prescribing provider (Crnich, 2012).  
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Many of the innovations of modern medicine are reliant on the ability of antibiotics to 
prevent or treat infections, especially in patients who may also be immunocompromised. 
Individuals who receive chemotherapy or dialysis, who undergo complex surgeries, such as 
cardiac bypass or joint replacements, who receive organ and or bone transplants, or who battle 
rheumatoid arthritis are at increased risk for acquiring an infection, and their lives often depend 
on effective antibiotic therapy (CDC, 2013b).  
Children are of particular concern regarding AR, because they have the highest rates of 
antibiotic use, and they are also at increased risk of developing antibiotic resistant, foodborne 
infections (CDC, 2011). Nearly 20% of Campylobacter infections and over 33% of nontyphoidal 
Salmonella infections occur in children under the age of ten (Shea, 2003). Ever since the U.S. 
entered Iraq and Afghanistan, the Military Health System has also faced increasing numbers of 
young, combat-injured soldiers who are colonized or infected with MDROs and plagued by 
persistent infections, lengthy hospitalizations, multiple surgical procedures, and resultant loss of 
limb and or life (Pew Charitable Trusts, 2012).  
Macro-level determinants that can propagate transmission of antibiotic resistant bacteria 
in correctional facilities and homeless shelters include overcrowding, poor sanitation, and a lack 
of observance of recommended sanitary procedures (Franco et al., 2009). Tuberculosis (TB) in 
correctional settings is a public health concern since individuals from diverse backgrounds and 
communities are housed in closed proximity and encounter frequent movement of inmates into 
and out of the facilities (CDC, 2012b). While still a rare occurrence in the U.S., there have been 
documented cases of MDR TB and XDR TB in prisons and homeless shelters, and for similar 
social and environmental reasons, the transmission of MRSA is also of concern to public health 
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officials in both of these populations (CDC, 2012a; Federal Bureau of Prisons, 2012; Society for 
Healthcare Epidemiology of America, 2012). 
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CHAPTER IV 
CURRENT AND FUTURE ACTIONS 
 
Organizational Initiatives 
 Numerous public health agencies have recognized the burgeoning threat of AR for years, 
and are amplifying their efforts to ensure that a diverse array of stakeholders are employed and 
engaged in sustaining efforts to foster awareness, resources, and action. The CDC’s Get Smart 
initiative has three programs intended to educate key partners and the public about the 
importance of judicious antibiotic prescribing and use in the community, healthcare facilities, 
and in agriculture (CDC, 2014e). A recently launched program, the Detect and Protect Against 
Antibiotic Resistance Initiative (AR Initiative), is part of the comprehensive CDC tactic to target 
investment marked for AR (CDC, 2014c). The goal is to outsmart AR promptly through four key 
actions supported by stakeholders: 
1. detect and track patterns of AR,  
2. respond to outbreaks involving antibiotic resistant bacteria,  
3. prevent infections from occurring and resistant bacteria from spreading, and  
4. discover new antibiotics and new diagnostic tests for resistant bacteria (CDC, 2014c).  
If requested funding is granted for the next five years, the CDC predicts the AR Initiative could 
attain a 50% reduction in healthcare-associated CRE infections, a 30% decrease in healthcare-
associated multi-drug resistant Pseudomonas, a 30% reduction in invasive MRSA, and a 25% 
decrease in multi-drug resistant Salmonella infections (CDC, 2014c). The CDC also participates 
in the NARMS, a collaboration among state and local health departments and national agencies, 
to track changes in the antimicrobial susceptibility of certain enteric (intestinal) bacteria found in 
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infected individuals (CDC), retail meats (U.S. FDA), and food animals (U.S. DA) in the U.S. 
(CDC, 2014f).  
 The Infectious Diseases Society of America (IDSA) has sponsored the 10 x ‘20 initiative, 
which requests a commitment from stakeholders in the U.S. and abroad, to cultivate a R&D 
venture that can produce ten new systemic antibiotics by the year 2020 (IDSA, n.d.a). The IDSA 
supports increased federal funding to fight AR and actions to coordinate U.S. surveillance, 
prevention and control, data collection, and research (IDSA, n.d.b). The IDSA also supports 
legislative passage of the proposed Strategies to Address Antimicrobial Resistance (STAAR) 
Act, which would financially ensure a robust and committed pledge from the government to 
directly act on this threat (IDSA, n.d.b). 
 Since global inaction, due to insufficient infrastructure and resources, and the reality that 
with modern transportation and shipping the occurrence of AR anywhere in the world can 
potentially impact AR in the U.S., it is necessary to include the efforts of the WHO. The WHO is 
collaborating with the World Organization for Animal Health and the Food and Agriculture 
Organization of the United Nations to identify best practices for optimizing the use of antibiotics 
in humans and agriculture, to temper the emergence of new resistant strains and the 
promulgation of existing antibiotic resistant bacteria (WHO, 2014a). In 2014, the WHO released 
its first report on AR with data from 114 countries and seven strains of resistant bacteria, and 
relayed findings that high levels of resistance exist in all areas of the world and substantial 
breaches exist in AR surveillance (WHO, 2014b). The WHO supports the use of incentives to 
generate development of new diagnostics, drugs, and vaccines, and the elimination of regulatory 
logjams to expedite review and licensure of new products (WHO, 2011). 
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Antibiotic Stewardship  
 The widespread development and implementation of antibiotic stewardship programs 
across the country is a vital action in the battle to tackle AR. Antibiotic stewardship consists of 
multifaceted, coordinated efforts to improve and measure the appropriate use of antibiotics by 
encouraging choice of the optimal drug, dose, duration of treatment, and route (Aziz, 2013). The 
CDC has identified seven key components that should be part of an effective antibiotic 
stewardship program (ASP), and program team members typically include an infectious disease 
physician, a pharmacist, and a microbiologist, but could also benefit from the inclusion and input 
of nursing and infection prevention specialists (Fridkin et al., 2014; Gillespie, Rodrigues, 
Wright, Williams, & Stuart, 2013). Historically, successful ASPs have been led by a physician 
who is accountable for program outcomes, but ASPs must also have committed senior leadership 
who can insure requisite resources (Fridkin et al., 2014). A dedicated pharmacist should 
collaborate with providers and laboratory personnel to implement interventions that require 
evaluation of antibiotic need after a set period of treatment (i.e., 48 hours), the tracking of 
prescribing habits and drug resistance patterns, and the timely reporting of this data to providers 
and nurses (Fridkin et al., 2014). Regular, up-to-date education must occur for healthcare 
workers to sustain awareness and garner buy-in for efforts to combat AR. Reduction strategies, 
which aim to narrow therapy from treatment with broad-spectrum, empirical choices, to narrow-
spectrum pathogen-driven coverage, can be bolstered by computer-aided programs that identify 
redundancy in prescriptions, susceptibility mismatches, or dosing errors (Bal & Gould, 2011). 
Antibiotic stewardship interventions have the capability to improve patient outcomes, diminish 
the detrimental effects of AR, and conserve fiscal resources, and existing programs have 
regularly reported annual cost savings to healthcare facilities of $200,000 to $400,000 (CDC, 
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2014b; CDC, 2014d). The CDC and IDSA recommend use or expansion of ASPs in all 
healthcare facilities, but currently there is an absence of coordinated, national legislation or 
regulatory mandates to promote AS (IDSA, 2014). 
Policy Change  
 Combatting AR will require a multi-pronged approach, and strong legislation is a critical 
step in the effort to make AR a public health priority. Public health advocates have repeatedly 
appeared before Congress to educate and stimulate awareness about the mounting peril of AR, 
and their urgent message has finally spurred action. In 2012, Congress enacted the Generating 
Antibiotic Incentives Now (GAIN) Act, which seeks to bolster the tenuous drug pipeline (Pew 
Charitable Trusts, 2013). This legislation prolongs by five years the exclusivity period, during 
which antibiotics that treat life-threatening infections can be sold devoid of competition from 
generic versions (Pew Charitable Trusts, 2013). Incentivizing actions, such as the GAIN Act, 
allow drug companies that develop novel antibiotics additional time to recoup their research and 
develop costs. As of September 2014, at least 23 antibiotics in development have been defined as 
qualified infectious disease products (QIDP), providing them market protection under GAIN, 
and three of these have achieved FDA approval (Pew Charitable Trusts, 2014b). In December 
2013, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act was introduced 
in the U.S. House of Representatives, with the goal of streamlining the regulatory process 
governing drug R&D. This bill aims to procure federal support for increased ease of access to 
new antibiotics for serious infections in limited, specific populations, when few effective 
treatments exist, by permitting them to be approved based upon results from smaller, more rapid 
clinical trials (Congress.gov., 2013; IDSA, 2013). Drugs receiving such approval would bear 
labels warning providers of their indication for use in designated patients, the U.S. FDA would 
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review the drug marketing materials, and evaluation metrics would be established to track 
provider-prescribing habits (Pew Charitable Trusts, 2014a).  
In September 2014, the Obama administration unveiled a comprehensive array of federal 
actions to focus on AR. The Executive Order includes establishment of a federal task force and 
Presidential Advisory Council to address AR; endorsement of antibiotic stewardship programs in 
healthcare and agriculture; buttressing national surveillance efforts and the capacity to respond to 
AR threats; provision of direction to cultivate novel antibiotics; and guidance to engage in 
international collaboration (WhiteHouse.gov., 2014). As part of this national strategy, the 
National Institutes of Health and the Biomedical Advanced Research & Development Authority 
will co-sponsor a $20 million award to stimulate the development of rapid, point-of-care 
diagnostics, which will aid providers in distinguishing highly resistant bacterial infections 
(WhiteHouse.gov., 2014). Both the CDC and the IDSA vigorously support robust regulatory 
action to complement other interventions. State-supported prevention collaboratives, consisting 
of multiple hospitals within a state, can also be a meaningful investment against AR by targeting 
infection through a team approach, implementing strategies via culture change, sharing 
experiences among facilities, and measuring group progress through benchmarks (CDC, 2014g). 
Lastly, public health agencies must advocate for the need to develop standard definitions and 
management of multi-drug resistant bacteria (Society for Healthcare Epidemiology of America, 
2014). Variations in definition can impact treatment, such as whether or not a patient is placed in 
isolation, which has ramifications not only for the individual hospital, but other facilities (i.e., 
rehabilitation centers, long-term care facilities) that frequently accept patient transfers. 
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Role of Nurses and Healthcare Workers 
It is essential that all healthcare professionals are well versed about the scientific basis of 
AR, how new resistance evolves and is dispersed, and are cognizant of tactics that can be 
employed to minimize this threat (Piddock, 2013). Regular continuing education must become a 
mandatory requirement for all staff, to apprise everyone about the importance of balancing 
proper use and preservation of antibiotics (Piddock, 2013). Additionally, educational institutions 
must insure that students understand how to use antibiotics effectively and realize the effects of 
usage extend far beyond the treated individual (Piddock, 2013). All healthcare workers share the 
onus to curtail the alarming progression of AR. However, nurses can play a pivotal role in 
affecting patients’ beliefs about their perceived need for antibiotics due to the significant amount 
of time they spend with patients and their caregivers, and because they are highly trusted and 
regarded by the public (Crombie, 2012). Nurses have an obligation to protect the health not only 
of the individual, but also to safeguard the welfare of the public (Hart, 2006). They can educate 
patients and caregivers about the appropriate use of antibiotics, including how antibiotics work 
and their effectiveness, how to self-manage viral infections, provide clear advice on how to take 
antibiotics as prescribed, and how to manage minor side effects that might prompt premature 
discontinuation (Crombie, 2012). In addition to providing patient education, nurses can help 
prevent the transmission of MDRO by following mandated infection control and isolation 
guidelines and insuring that fellow healthcare workers always observe infection control 
standards (Glover, 2000). Physicians and advanced practitioners must apply the tenets of 
antibiotic stewardship when treating patients, and resist the manipulative tactics of patients and 
parents who seek unfettered access to a quick fix for illness. Finally, a return to scrupulous hand 
hygiene practices could reduce both the burden of infection and the spread of antibiotic resistant 
33 
 
bacteria. MDROs can easily be spread from patient to patient on the hands of healthcare workers 
through direct contact or contaminated equipment, yet studies have found that best practice hand 
hygiene guidelines are only followed about 40% of the time (University of North Carolina 
Gillings School of Global Public Health, 2014). Healthcare facilities must demand that anything 
less than complete adherence to established hand hygiene policies is a violation of basic infection 
control practices and necessitates accountability (Sandora & Goldmann, 2012). Facility 
leadership must also assure that in times of scarce resources, sufficient funding must be allocated 
to sustain infection control measures, since this almost consistently results in both the 
containment of antibiotic resistant bacteria and decreased mortality rates (Hawkey, 2008). 
Public Awareness and Accountability 
 While education alone is not a sufficient intervention, public educational and awareness 
campaigns can generate awareness about AR and facilitate understanding of why a prescriber 
may withhold antibiotic treatment. A reorientation of social norms and behavior will be a critical 
step in making strides to curb widespread antibiotic use in healthcare and agriculture. 
Interventions to alleviate the perils of resistance will likely result in perceived inconvenience and 
actual costs to the public through the more judicious allocation of antibiotics and the higher 
direct costs of agricultural products due to practice modifications.  
Healthcare consumers must realize that they also play a central role in fighting AR by 
sensible use of antibiotics. This includes allowing providers to make unpressured decisions as to 
when antibiotics are necessary, taking only currently prescribed antibiotics exactly as ordered, 
and by practicing good hand hygiene. The public can also be vigilant in staying current with 
recommended vaccinations, since some vaccines can prevent bacterial illnesses and antiviral 
vaccines can prevent illnesses that may mimic bacterial infections, prompting unneeded 
34 
 
antibiotic therapy (Drugs.com, 2014). Because infection lacks a clear advocacy group, unlike 
other health threats such as heart disease or cancer, it often spawns minimal support or concern 
from the public (Tillotson, 2013). Public health advocates must therefore find a way to show the 
public how increased risk of death or lengthy hospitalizations are tied to the vast overuse of 
antibiotics, and these undesirable outcomes will become more commonplace in the near future, 
without urgent, concerted interventions (Tillotson, 2013). 
Research and Design of Novel Drugs and Diagnostics  
The ability to effectively fight back against AR is also contingent upon the development 
of new antibiotics and diagnostic tests. Because AR is part of a natural evolutionary process and 
will continue to occur as long as antibiotics are utilized, it is imperative the R&D process is 
supported by federal and private incentives to stimulate innovation in industry and academia. 
Both larger pharmaceutical companies and smaller biotechnology firms have been hampered by 
the high costs and low returns associated with developing new antibiotics for the most resistant 
infections versus drugs for chronic conditions, and the regulatory challenges requiring cost-
prohibitive studies (Boucher et al., 2009). Incentives that support a sustainable R&D 
infrastructure and public-private partnerships may entice venture capitalists and other investors 
to join in the quest for solutions both nationally and globally as public health interests continue 
to compete for finite resources (Boucher et al., 2009). New diagnostics, such as PCR-based tests, 
point-of-care tests, and mass spectrometry, have the ability to identify AR threats quicker than 
the diagnostics used in current practice throughout much of the U.S. (CDC, 2013b). Advanced 
technologies have the potential to directly impact patient care by rapidly aiding providers in not 
prescribing antibiotics, or opting for narrow spectrum therapy, but laboratory results can also be 
used to apprise local, regional, and national surveillance systems. Business goals and 
35 
 
technological needs must be aligned to aid in developing, planning, and coordinating diagnostic 
tests that are ideally efficient, sensitive, specific, reasonably priced, and user friendly 
(Laxminarayan et al., 2013). It will also prove beneficial to the R&D process if the U.S. FDA 
and the European Medicines Agency (EMA) collaborate to mitigate barriers to approval and 
market entry for drugs targeting MDROs and if stakeholders relinquish their traditional solo 
approach to R&D and participate in partnerships among academia, smaller operations, and “big 
Pharma” (ReleaseWire LLC., 2013). Greater investment in R&D of novel drugs and rapid 
diagnostics will lead to improved patient outcomes, moderated healthcare costs, and reduced AR. 
Conclusions 
The discovery of antibiotics almost a century ago was a life-changing event, yet years of 
rampant and effective antibiotic therapy has created a sense of complacency where the power of 
antibiotics is taken for granted, among the public and many members of the healthcare, 
agriculture, and pharmaceutical industries. All stakeholders must be educated about the serious 
and life-threatening hazards of AR, because ignorance and uninformed opinion will only fuel 
reckless antibiotic use, jeopardizing the public’s health (Piddock, 2013). The generation and 
dissemination of reliable, relevant, and timely information, the sustained regulatory and financial 
support from the federal level, and the pursuit of new antibiotics and diagnostics will be key in 
mounting an effective response to the rapidly intensifying threat of AR on the public’s health. 
Without broad, concerted awareness and action now, the days in which antibiotics revolutionize 
healthcare will be overshadowed by a new age where the ability to treat infections is lost. 
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APPENDIX A 
 
COMMONLY USED BROAD-SPECTRUM AND NARROW-SPECTRUM 
ANTIBIOTICS 
 
Type of Antibiotic Commonly Used Name 
Broad-spectrum Antibiotics • Amoxicillin 
• Levofloxacin 
• Streptomycin 
• Tetracycline 
Narrow-spectrum Antibiotics • Azithromycin 
• Clarithromycin 
• Clindamycin 
• Erythromycin 
• Vancomycin 
 
Source: SRS Pharmaceuticals PVT. LTD (2014) 
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APPENDIX B 
MINIMUM ESTIMATES OF MORBIDITY AND MORTALITY IN THE U.S. 
 
Threat Level Antibiotic Resistant Organism Estimated 
Annual Number 
of Cases 
Estimated 
Annual Number 
of Deaths 
 
Urgent 
• Carbapenem-resistant 
Enterobacteriaceae (CRE) 
9,300 610 
• Drug-resistant  Neisseria 
gonorrhoeae 
246,000 <5 
 
 
 
 
 
 
 
 
 
Serious 
• Multi-drug resistant 
Acinetobacter 
7,300 500 
• Drug-resistant Campylobacter 310,000 28 
• Extended spectrum β-lactamase 
producing Enterobacteriaceae 
(ESBLs) 
26,000 1,700 
• Vancomycin-resistant 
Enterococcus (VRE) 
20,000 1,300 
• Multi-drug resistant  
Pseudomonas aeruginosa 
6,700 440 
• Drug-resistant Non-typhoidal 
Salmonella 
100,000 40 
• Drug-resistant Salmonella Typhi 3,800 <5 
• Drug-resistant Shigella 27,000 <5 
• Methicillin-resistant 
Staphylococcus aureus (MRSA) 
80,000 11,000 
• Drug-resistant Streptococcus 
pneumoniae 
1,200,000 7,000 
• Drug-resistant tuberculosis 1,042 50 
 
 
 
Concerning 
• Vancomycin-resistant 
Staphylococcus aureus (VRSA) 
<5 <5 
• Erythromycin-resistant Group A 
Streptococcus 
1,300 160 
• Clindamycin-resistant Group B 
Streptococcus 
7,600 440 
 
Source: CDC (2013b) 
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